

**MASTER MATERIAL TRANSFER AGREEMENT FOR THE TRANSFER OF MATERIALS FROM
NINDS BIOSEND**

This Master Material Transfer Agreement for the transfer of Materials from NINDS BIOSEND (“Master Agreement”) is made and entered into by and between The Trustees of Indiana University having offices at 509 E. 3rd St., Bloomington, IN 47401, USA (hereinafter “IU”) and the Recipient Institution identified on the signature page below (“Recipient Institution”) in the interest of the Recipient Investigator identified on the signature page below (“Recipient Investigator”). This Agreement is effective as of date of the last signature below (“Effective Date”).

WHEREAS, IU operates the NINDS Biospecimen Exchange for Neurological Disorders (“NINDS BIOSEND”), a biorepository located within Indiana University and originally established through funding from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH), an agency of the Public Health Service (PHS) and the U.S. Department of Health & Human Services (HHS), to help address the public health needs for continued research concerning Parkinson’s disease (PD), Huntington’s disease (HD), traumatic brain injury (TBI) and other neurological and neuropsychiatric diseases; and

WHEREAS, NINDS BIOSEND receives biological material from humans and Associated Phenotypic Data (as defined below) submitted by public and private sector investigators; and

WHEREAS, NINDS BIOSEND and associated IU laboratories analyze the NINDS BIOSEND Research Material contemplated under this Agreement and its Appendices for purposes of producing and obtaining Biospecimen Data; and

WHEREAS, IU desires to distribute this biological material, Biospecimen Data, and Associated Phenotypic Data to Recipient Institution solely for use under the direction and supervision of Recipient Investigator for research which may include determination of Biospecimen Data and/or isolation of Derived Materials (as defined below); and

WHEREAS, NINDS has designated certain sites for the deposit of all Genetic Data determined or identified by investigators using the NINDS BIOSEND Research Material and such sites include, but are not limited to NINDS approved sites including, but not limited to, the database of Genotype and Phenotype (dbGaP) (developed through NIH to archive and distribute the results of studies that have performed Genome Wide Association Studies (GWAS) and Genomic Data <http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap>) and the Data Management Resource (DMR; <http://pdbp.ninds.nih.gov/>) using the NINDS BIOSEND Research Materials; and

WHEREAS, Recipient Institution, contingent upon Recipient Investigator being found to be a qualified investigator as determined by an approved advisory committee, desires to obtain NINDS BIOSEND Research Material for use in Recipient Investigator’s research.

NOW, THEREFORE, in consideration of the mutual promises contained herein, and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, IU will provide Recipient Institution with the agreed upon NINDS BIOSEND Research Materials subject to the following terms and conditions:

Definitions:

“Associated Phenotypic Data” shall mean deidentified data on family structure, age, sex, vital status, psychopathology, diagnosis, and other clinically relevant associated phenotypic information, stripped of all personal identifiers and thus unlinkable to the individuals from whom they were obtained.

“Biospecimen Data” shall mean de-identified data derived from all analyses of the NINDS BIOSEND Research Material as obtained or determined by Recipient Investigator and other scientists under his/her

direction and supervision, stripped of all personal identifiers and thus unlinkable to the individuals from whom they were obtained.

“NINDS BIOSEND Research Material” shall mean the biological material from humans including the biological samples and the Associated Phenotypic Data transferred from IU’s NINDS BIOSEND facility to Recipient Institution (jointly referred to herein as “Original Research Material”) as well as Progeny and/or Unmodified Derivatives thereof, including stem cells derived therefrom. Unmodified Derivatives may also be referred to herein as “Derived Materials.”

“Derived Material” (also referred to herein as Unmodified Derivatives) shall mean substances created or isolated by the Recipient Institution which constitute an unmodified functional subunit or product of the Original Research Material. Some examples include but are not limited to: stem cells, subclones of unmodified cell lines, purified or fractionated subsets of the biological samples of the Original Material, any and all genetically unmodified cells or cell lines created by or isolated from use of the biological samples of the Original Research Material. For the purposes of this Agreement, Unmodified Derivatives shall not include any progenitor cells derived from iPSCs.

“Progeny” shall mean unmodified descendant from the NINDS BIOSEND Research Material, such as cell from cell, or organism from organism.

“Progenitor cell” shall mean the derivative of an iPSC that will further differentiate to create a specialized cell type.

“Commercial Purposes” shall mean the sale, lease, license or other exploitation including but not limited to use, in whole or in part of the NINDS BIOSEND Research Material, directly or indirectly, including any NINDS BIOSEND Research Material contained or incorporated in Modifications, to a party for potential product development or profit-generating purpose, including, but not limited to, use of the NINDS BIOSEND Research Material by Recipient Institution to perform contract research, to screen compound libraries, to develop, produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license or transfer of the NINDS BIOSEND Research Material to any other party. However, industry sponsored academic research shall not necessarily be considered a Commercial Purpose unless such research is contrary to the terms and conditions of this agreement.

Terms and Conditions of Agreement:

1. The control and distribution of NINDS BIOSEND Research Material is the responsibility of IU through the NINDS BIOSEND facility and is made available as a service to qualified individuals in the research community to further research of Parkinson’s disease (PD), Huntington’s disease (HD), and traumatic brain injury (TBI) and other neurological and neuropsychiatric diseases.
2. IU and Recipient Institution agree that all NINDS BIOSEND Research Materials that transfer from IU to Recipient Institution under this Master Agreement will be described specifically on an ADDENDUM TO THE MASTER MATERIAL TRANSFER AGREEMENT: NINDS BIOSEND RESEARCH MATERIAL TO BE PROVIDED BY IU TO RECIPIENT INSTITUTION FOR THE BENEFIT OF RECIPIENT INVESTIGATOR, attached hereto and incorporated herein as an Appendix C. Subsequent requests for additional NINDS BIOSEND Research Material under this Master Agreement shall require submission of an additional Appendix C. Therefore, there may be multiple Appendix C documents attached to the Master Agreement; each will be signed by the same Recipient Investigator and a NINDS BIOSEND Investigator and will be subject to the terms and conditions of this Master Agreement. IU shall provide Recipient Institution with NINDS BIOSEND Research Material described on a signed Appendix C. IU shall have sole discretion whether or not to add a new Appendix C under this Master Agreement.

3. NINDS BIOSEND Research Material represents a significant investment on the part of those who deposited the material with NINDS BIOSEND and others, including the NIA and NIH. The NINDS BIOSEND Research Material is provided to Recipient Institution under this Master Agreement solely for use by Recipient Investigator, identified on the signature page below, or others at Recipient Institution as approved by Recipient Investigator in furtherance of research related to Parkinson's disease (PD), Huntington's disease (HD), and traumatic brain injury (TBI) and related neurological and neuropsychiatric diseases and aging, such research as specifically described in an Appendix C ("Research Project"), attached hereto and incorporated herein. To be clear, each Appendix C signed by Recipient Investigator and NINDS BIOSEND Investigator shall list NINDS BIOSEND Research Materials that will transfer from IU to Recipient Institution and the Research Project for which they will be used by the Research Investigator and those under his/her direction and supervision under the terms and conditions of this Master Agreement.
4. NINDS BIOSEND Research Material may not be used in experiments involving human subjects. The Recipient Institution agrees to comply with all Federal and state rules and regulations applicable to the use and handling of the NINDS BIOSEND Research Material.
5. Research Institution agrees to use the NINDS BIOSEND Research Material, including the Original Research Material, Progeny, and Derived Materials, for Research Project purposes only. NINDS BIOSEND Research Material shall not be used for Commercial Purposes. No right, title or interest in and to the NINDS BIOSEND Research Material shall transfer to the Recipient Institution.
6. Subject to paragraph 3 of this Master Agreement, the NINDS BIOSEND Research Material, including the Original Material as well as their Progeny and Unmodified Derivatives thereof, including stem cells derived therefrom, shall not be further distributed to any other person or entity by the Recipient Institution or Recipient Investigator without NINDS BIOSEND's prior written consent. The Recipient Institution or Recipient Investigator agrees to refer any such request for the NINDS BIOSEND Research Material to NINDS BIOSEND. For the avoidance of doubt, this transfer restriction shall not apply to transfer of progenitor cells.
7. Recipient Investigator using NINDS BIOSEND Research Material under this Master Agreement shall share Biospecimen Data derived from the Research Project by placing these Biospecimen Data and Associated Phenotypic Data in NIAGADS, or another NIA approved site, or all such sites. All approved sites will make these Biospecimen Data and Associated Phenotypic Data available to qualified investigators in the scientific community for secondary analysis in accordance with standards established by the NIA. The Recipient Investigator agrees to provide such Biospecimen Data as soon as reasonably possible, but no later than immediately upon acceptance of a subset of data for publication or public disclosure of a submitted patent application, whichever is earlier. When a genome wide association study or next generation sequencing has been performed, the Recipient Investigator agrees to abide by any current NIH-adopted policy concerning sharing of genetic data obtained in NIH supported studies.
8. Transfer of Derived Material to NINDS BIOSEND. If Recipient Institution, Recipient Investigator, or those under the direction and supervision of the Recipient Investigator at the Recipient Institution, develops Derived Material (including, but not limited to, stem cells) under this Master Agreement, including any Appendix C attached hereto, then Recipient Institution and Recipient Investigator agree to transfer said Derived Material to NINDS BIOSEND under the terms and conditions of the MATERIAL TRANSFER AGREEMENT FOR THE TRANSFER OF DERIVED MATERIALS TO NINDS BIOSEND, attached hereto and included herein as Appendix F. The Recipient Investigator agrees to provide NINDS BIOSEND samples of such Derived Material as soon as possible, but no later than one year after publication or oral presentation describing Derived Material. The Derived Material transferred from Recipient Institution to NINDS BIOSEND will consist of at least two vials of Derived Materials accompanied by documentation adequate to enable NINDS BIOSEND investigators to culture and/or maintain Derived Material. Derived Material does not need to be transferred to NINDS BIOSEND under this Section if, and only if, (i) the biological

sample transferred from IU's NINDS BIOSEND facility to the Recipient Institution, from which the Derived Material was created or isolated, was DNA, or (ii) Recipient has obtained NINDS BIOSEND's prior written consent to not transfer the Derived Materials. Recipient Investigator shall not provide Derived Material to any other party.

9. Transfer of Biospecimen Data from NINDS BIOSEND. The de-identified Biospecimen Data will be transferred from NINDS BIOSEND to the Recipient Investigator. NINDS BIOSEND will retain a copy of the de-identified Biospecimen Data in its data repository. Recipient Institution will endeavor not to re-associate the de-identified Biospecimen Data with any of the Recipient Institution's raw data and will promptly report any event in which re-identified data has been unlawfully or inappropriately disclosed to any third party.
10. Recipient Investigator will acknowledge the contribution of NINDS BIOSEND, all institutions contributing to NINDS BIOSEND, and the NIA in any and all oral and written presentations, disclosures, and publications resulting from any and all use and analyses of the NINDS BIOSEND Research Material, as well as any data received from NINDS BIOSEND. Acknowledgement language to be used is that set forth in Appendix G attached hereto and incorporated herein. From time-to-time, the language of Appendix G may be modified and such modification shall have no effect on the remaining provisions of this Master Agreement which shall continue in full force and effect. Except as otherwise provided herein, authorship of any publications shall be determined by academic standards as set forth by the International Committee of Medical Journal Editors (ICMJE) guidelines. It is expected that studies using biomarker assay data include scientists from the biomarker laboratory in drafting or revising of manuscripts for important intellectual content and each Party shall in good faith review and take a Party's comments into consideration. Providing Institution agrees that any proposed publication or presentation relating to the NINDS BIOSEND Research Material conducted under this Agreement will be submitted to the biomarker laboratory scientists for review at least thirty (30) days prior to submission for publication or presentation to remove confidential information. As such, the scope of confidential information in this publication context does not include the results arising out of the performance of this Agreement.
11. Any NINDS BIOSEND Research Material delivered pursuant to this Master Agreement is understood by Recipient Institution to be experimental in nature and may have hazardous properties. All cultured animal and human tissue cells have the potential for carrying viruses, latent viral genomes, and other infectious agents in a non-apparent state. By accepting NINDS BIOSEND Research Material, the undersigned Recipient Institution assumes full responsibility for the safe and appropriate handling of the NINDS BIOSEND Research Material. THE PARTY WHO ORIGINALLY DEPOSITED THE NINDS BIOSEND RESEARCH MATERIAL WITH NINDS BIOSEND, NINDS BIOSEND, AND THE TRUSTEES OF INDIANA UNIVERSITY MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED INCLUDING, BUT NOT LIMITED TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE RESEARCH MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. Unless prohibited by law, Recipient Institution assumes all liability for claims for damages against it by third parties which may arise from Recipient Institution's use, storage or disposal of the Research Material except that, to the extent permitted by law, IU shall be liable to the Recipient Institution when the damage is caused by the gross negligence or willful misconduct of IU.
12. The Recipient Institution and Recipient Investigator agree that the NINDS BIOSEND Research Material including the biological samples and the Associated Phenotypic Data shall not be used either alone or in conjunction with any other information, in any effort whatsoever to establish the individual identities of any subjects from which the NINDS BIOSEND Research Material was derived. In addition, should Recipient Institution or Recipient Investigator receive information that could result in identification of any subject from which the NINDS BIOSEND Research Material was derived, then Recipient Institution and Recipient Investigator agree to refrain from providing such

individual(s) with any NINDS BIOSEND related Research Material data or results.

13. IU may terminate a particular Appendix C or the Master Agreement if the Recipient Institution is in default of any of the terms specified herein and if the deficit has not been remedied within thirty (30) days after Recipient Institution's receipt of written notice by IU of such deficit. Upon termination under this clause, the Recipient Institution agrees to destroy all unused NINDS BIOSEND Research Material, including accompanying Associated Phenotypic Data, Progeny and Derived Materials, and Recipient Investigator shall provide NINDS BIOSEND with written certification of their destruction, unless permission to retain NINDS BIOSEND Research Material is specifically provided in writing by IU to Recipient Institution. Obligations of Recipient Institution under clauses 5-11 shall survive termination. Subjects from whom NINDS BIOSEND Research Material has been derived and provided to NINDS BIOSEND may decide to withdraw consent for use of NINDS BIOSEND Research Material. In the event NINDS BIOSEND is notified that consent for use of NINDS BIOSEND Research Material has been withdrawn, NINDS BIOSEND may notify all recipients of that particular NINDS BIOSEND Research Material and then the Recipient Institution shall immediately destroy the applicable NINDS BIOSEND Research Material, including the Original Material, Progeny, Derived Material and Associated Phenotypic Data. Upon NINDS BIOSEND's request Research Institution shall provide NINDS BIOSEND with a written certification of destruction.
14. The NINDS BIOSEND Research Material identified in each Appendix C is provided with a transmittal fee for Research Institution to reimburse NINDS BIOSEND in a cost-recovery model for preparation and distribution of samples. Each transmittal fee, one for each Appendix C, shall be mutually agreed to by the parties to this Master Agreement in order for NINDS BIOSEND Research Material identified in each Appendix C to be shipped.
15. This Master Agreement and attached Appendices constitutes the entire agreement and understanding of the parties and supersedes any prior agreements, promises or understandings, written or verbal, relating to the subject matter hereof. This Master Agreement and any attachments hereto/thereto may not be amended or waived in whole or in part, except in writing signed by both parties.
16. This Master Agreement is intended to be severable, and the invalidity and/or unenforceability of any clause of this Master Agreement, or part thereof shall not affect the validity and/or enforceability of any other clause or part thereof to the extent not invalidated or held unenforceable.
17. This Master Agreement or attachments thereto may be executed in counterparts, each of which shall be deemed to be an original, and all of such counterparts shall together constitute one and the same agreement.
18. This Master Agreement is not assignable, whether by operation of law or otherwise, without the consent of the other party hereto (which shall not be unreasonably withheld, or denied).

Signatures on Following Page

IN WITNESS WHEREOF, the parties have executed this Master Agreement as of the Effective Date by their authorized representatives.

RECIPIENT INSTITUTION

Business Address of Recipient Institution:

Name of Recipient Institution:

By: _____

Authorized Official of Recipient Institution

Name:

Title:

Date:

Certification of Recipient Investigator: I have read and understood the conditions outlined in this Master Agreement and I agree to abide by them in the receipt and use of the NINDS BIOSEND Research Material including the Progeny, Derived Materials and Associated Phenotypic Data.

RECIPIENT INVESTIGATOR

Shipping Address:

Read and Understood

By: _____

Name:

Title:

Date:

THE TRUSTEES OF INDIANA UNIVERSITY

By: _____

Authorized Official of Recipient Institution

Name:

Title:

Date:

NR _____

Read and Understood

By: _____

NINDS BIOSEND Investigator

Name:

Title:

Date:

LEGAL ADDRESS:
Office for Research Administration
509 E. 3rd St.
Bloomington, IN 47401
oraresco@iu.edu

NINDS BIOSEND ADDRESS
(Programmatic Correspondence)
Division of Hereditary Genomics
Indiana University
410 West 10th Street, HS 4000
Indianapolis, IN 46202-3002

APPENDIX C

ADDENDUM TO THE MASTER MATERIAL TRANSFER AGREEMENT: NINDS BIOSEND RESEARCH MATERIAL TO BE PROVIDED BY IU TO RECIPIENT INSTITUTION FOR THE BENEFIT OF RECIPIENT INVESTIGATOR

This Appendix C is effective as of the date of the last signature below (“Appendix C Effective Date”) and is governed by terms and conditions of the “Master Material Transfer Agreement for the Transfer of Materials From NINDS BIOSEND” with an Effective Date of _____ (hereinafter “Master Agreement”) between The Trustees of Indiana University (herein, “IU”) and Recipient Institution identified in the signature block (jointly referred to as parties) in the interest of the Recipient Investigator identified on the signature page below. The parties agree as follows:

1. The parties to this Appendix C are parties to the Master Agreement identified above and desire to execute this Appendix C under the terms and conditions of said Master Agreement. Except as defined in this Appendix C, all other capitalized terms shall be as defined in the Master Agreement.
2. The materials to be provided by NINDS BIOSEND are non-toxic and non-hazardous. These samples were collected from willing research study participants according to the principles of the ICH guidelines on Good Clinical Practice. To the best of our knowledge, the specimens were only taken from persons with no signs or symptoms of the following diseases: Cholera, Highly pathogenic avian influenza in humans (HPAIIH), Human swine influenza with pandemic potential, Plague, Rabies, Severe acute respiratory syndrome (SARS), Small pox, Viral haemorrhagic fever in humans, Yellow fever, or any disease that is exotic to the country of destination.
3. **The terms and conditions of the Master Agreement shall govern this Appendix C.**
4. Recipient Institution desires to obtain and IU agrees to provide the materials listed below (using specific identifiers for each material) to be included in NINDS BIOSEND Research Material.
5. If either party needs revisions to Appendix C regarding sample quantity, an amended Appendix C can be reissued for signatures.

RECIPIENT INVESTIGATOR and RECIPIENT INSTITUTION INFORMATION

Recipient Investigator Name (Printed):

Phone:

Fax:

E-mail address:

Recipient Institution Name:

Shipping Address for receipt of the Research Materials:

Please list the NINDS BIOSEND Research Material(s) being requested by the Recipient Institution (using specific identifiers for each Research Material) (attach separate page(s) as necessary):

Please describe the non-commercial research to be conducted by the Recipient Investigator (“Research Project”) using the NINDS BIOSEND Research Material(s) listed above (attach separate page(s) as necessary):

Please describe the specific Biospecimen Data that will be sought in the Research Project described above (attach separate page(s) as necessary):

SIGNATURES

Certification of Recipient Investigator: I have read and understood the conditions outlined in the Master Agreement to which this Appendix C is attached and incorporated and I agree to abide by the terms and conditions of the Master Agreement in the receipt and use of the NINDS BIOSEND Research Material described in this Appendix C, including the Progeny, Derived Material, and Associated Phenotypic Data.

Recipient Investigator Signature

Date

Recipient Investigator Name

Recipient Investigator Title

NINDS BIOSEND INVESTIGATOR INFORMATION and SIGNATURE

Name & Title of NINDS BIOSEND Investigator:

Signature of NINDS BIOSEND Investigator

Date

APPENDIX F: To be used, when Recipient Institution of Master Agreement (herein Appendix F referred to as “Provider”) transfers Derived Material to IU at the NINDS BIOSEND facility.

APPENDIX F

**MATERIAL TRANSFER AGREEMENT
FOR THE TRANSFER OF DERIVED MATERIALS TO NINDS BIOSEND**

This Material Transfer Agreement for the Transfer of Derived Materials to NINDS BIOSEND (“Appendix F”) is made and entered into by and between the Trustees of Indiana University having offices at 509 East 3rd Street Bloomington IN 47401-3654, USA (hereinafter “IU”) and the Providing Institution identified on the signature page below (“Provider”) jointly referred to as the parties. This Appendix F is effective as of date of the last signature below (“Appendix F Effective Date”) and results from the terms and conditions of the “Master Material Transfer Agreement for the Transfer of Materials from NINDS BIOSEND” between the parties with an Effective Date of _____ hereinafter “Master Agreement”).

Whereas IU operates the NINDS Biospecimen Exchange for Neurological Disorders (NINDS BIOSEND), a biorepository located within Indiana University and which was originally established through funding from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH), an agency of the Public Health Service (PHS) and the U.S. Department of Health & Human Services (HHS), to help address the public health needs for continued research concerning Parkinson’s disease (PD), Huntington’s disease (HD), traumatic brain injury (TBI) and other neurological and neuropsychiatric diseases;

Whereas IU provided Original Research Material to Provider;

Whereas Provider generated Derived Materials (as defined in Master Agreement) under the terms and conditions of the Master Agreement;

Whereas Provider agreed in the Master Agreement to transfer Derived Materials (defined in Master Agreement) to IU at their NINDS BIOSEND facility for distribution by NINDS BIOSEND to nonprofit and for-profit organizations for furthering non-commercial research concerning Parkinson’s disease (PD), Huntington’s disease (HD), and traumatic brain injury (TBI) and other neurological and neuropsychiatric diseases;

Whereas Provider has obtained and generated Derived Material in compliance with all applicable statutes, rules, and regulations; and

Whereas Provider desires NINDS BIOSEND, after consultation with the NIA and the relevant NINDS BIOSEND advisory committee, to distribute Derived Material to qualified investigators in the research community.

Now Therefore, Provider and IU enter into this Appendix F governing the transfer and use of Derived Material.

1. The parties to this Appendix F are parties to the Master Agreement identified above and desire to execute this Appendix F as a result of the terms and conditions of the Master Agreement. Except as defined herein, all other capitalized terms shall be as defined in the Master Agreement.
2. The terms and conditions of this Appendix F shall be consistent with the Master Agreement.
3. Provider agrees, at its own expense, to transfer to IU (at the NINDS BIOSEND facility) at least two vials of the Derived Material(s) listed below as well as documentation adequate to enable NINDS BIOSEND investigators to culture and/or maintain Derived Material. At any time, with the consent of IU, Provider may transfer additional vials of the same listed Derived Materials to IU under this Appendix F.

List Derived Materials: (Attach additional sheet if needed).



4. DERIVED MATERIAL MAY NOT BE USED IN EXPERIMENTS INVOLVING HUMAN SUBJECTS. IU agrees to comply with all Federal rules and regulations applicable to the use and handling of the Derived Material.
5. Derived Material will be used by NINDS BIOSEND solely for teaching, noncommercial research purposes, and for subsequent distribution restricted to not be for Commercial Use. NINDS BIOSEND will prepare and maintain Derived Material as appropriate in its facility and will ship Derived Material to third party requesters under the terms and conditions of MASTER MATERIAL TRANSFER AGREEMENT FOR THE TRANSFER OF MATERIALS FROM NINDS BIOSEND.
6. Derived Material transferred from Provider to IU pursuant to this Appendix F is understood to be experimental in nature and may have hazardous properties. PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED INCLUDING, BUT NOT LIMITED TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE DERIVED MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. Unless prohibited by law, IU assumes liability only for claims for damages which may arise from the use, storage, or disposal of the Derived Material by IU to the extent permitted by law. All cultured animal and human tissue cells have the potential for carrying viruses, latent viral genomes, and other infectious agents in a non-apparent state. Accordingly, IU shall adhere to the applicable guidelines for appropriate laboratory procedure.
7. This Appendix F may be executed in counterparts, each of which shall be deemed to be an original, and all of such counterparts shall together constitute one and the same agreement.

Signatures on following page

IN WITNESS WHEREOF, the parties have executed Appendix F as of the Effective Date by their authorized representatives.

PROVIDER:

By: _____
Authorized Official of Provider
Name: _____
Title: _____
Date

THE TRUSTEES OF INDIANA UNIVERSITY

By: _____
Authorized Official
Name: _____
Title: _____
Date

Read and Understood

Signature of NINDS BIOSEND Investigator
Name: _____
Title: _____
Date

LEGAL ADDRESS:

Office for Research Administration

509 East 3rd Street

Bloomington, IN 47401-3654

oraresco@iu.edu

NINDS BIOSEND ADDRESS (Programmatic Correspondence)

Division of Hereditary Genomics

Indiana University

410 West 10th Street, HS 4000

Indianapolis, IN 46202-3002



APPENDIX G

Acknowledgement of Grant Support

According to Section 10 of the Master Agreement, Recipient Investigator will acknowledge the contribution of various parties in any and all oral and written presentations, disclosures, and publications resulting from use of the NINDS BIOSEND Research Material using the following language:

NINDS BIOSEND grant acknowledgement for all samples obtained from NINDS BIOSEND: Samples from the NINDS BIOSEND, which receives government support under a cooperative agreement grant (U24 NS095871) awarded by the National Institute of Neurological Disorders and Stroke (NINDS), were used in this study. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible.

The following grants, as checked, which supported the collection of samples included in Research Material shall also be acknowledged.

Check all that apply:

- The NINDS Parkinsons Disease Biomarkers Program (NINDS PDBP): Data and biospecimens used in preparation of this manuscript were obtained from the Parkinson's Disease Biomarkers Program (PDBP) Consortium, part of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Investigators include: (please add the names of all investigators found at the following link – https://pdbp.ninds.nih.gov/sites/default/files/assets/policy/PDBP_publication_policy.pdf). The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript.

Prior to Journal publication the manuscript must be submitted to the PDBP Steering Committee (via PD-Pubs@ninds.nih.gov) who will verify within 5 days that the PDBP is appropriately acknowledged. If this time elapses without notice from the PDBP Steering Committee Representatives, authors may proceed with the paper.

- The BioFIND Project: Per the BioFIND project Data Use Agreement (see <https://www.michaeljfox.org/files/NEWBioFIND%20Data%20Use%20Agreement.pdf>): BioFIND is funded by The Michael J. Fox Foundation for Parkinson's Research and the National Institute Neurological Disorders and Stroke.
- The NINDS Udall Centers: Data and samples used in this study were collected in part via the National Institute of Neurological Disorders and Stroke Udall Centers of Excellence in Parkinson's Disease Program.
- PREDICT-HD: Samples used in this study were in part collected via the PREDICT-HD study (U01 NS082089). All manuscripts submitted, in addition to the appropriate authors, will acknowledge the Predict HD study investigators followed by an asterisk. The asterisk will point to a printed and/or, in a case of an electronic publication, web site https://neurology.wisc.edu/wp-content/uploads/2023/05/PREDICT-HD_2020_Acknowledgments.pdf (if allowed by the journal) listing the names of Predict HD study investigators.
- 2-CARE: Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Numbers NS052592 and NS052619 [(Cudkowicz, Mass General Hospital) and (McDermott; Rochester, Coordinating and Biostatistics), respectively.
- FTD-TAU Cohort: These samples were collected, in part, via the Early Symptoms of FTL D Study (R01 NS076837).
- READISCA: The READISCA study supported the collection of samples used in this study through National Institute of Neurological Disorders and Stroke (NINDS) grant NS104326. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. The READISCA collection is currently housed at the NINDS BIOSEND repository at Indiana University under



grant U24NS095871.

- CRC-SCA: The CRC-SCA Research Consortium: Data and biospecimens used in this study were collected via The National Ataxia Foundation funded CRC-SCA consortium (<https://www.ataxia.org/crc-sca>). We kindly acknowledge the patients involved in this consortium for their generous contributions to this work.
- LETBI: National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) (1RF1NS115268-01), Clinical & Biological Signatures of post-traumatic neurodegeneration: Toward in-vivo diagnosis of the Late Effects of TBI (LETBI).
- NINDS BIOSEND only as stated above.

